Lymphoma Clinical Trials

Showing 1661-1680 of 2,926 trials

A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors

NCT00503451

The primary purpose of this open-label study is to investigate the interaction of ketoconazole, a liver enzyme inhibitor, on oral LBH589 in adult patients with advanced solid tumors. The extension phase of the study will evaluate the safety and efficacy of LBH589 in patients with advanced solid tumors.

Non-Hodgkin LymphomaNeoplasms

Novartis Pharmaceuticals14 participantsStarted Sep 2007

Las Vegas, Nevada, United States • Rotterdam, Netherlands

COMPLETEDPhase 1

Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)

NCT01634763

Estimation of the Maximum tolerated dose (MTD) and/or Recommended dose (RD) of LDK378 as a single agent when administered orally to Japanese patients with tumors characterized by genetic alterations in anaplastic lymphoma kinase (ALK)

Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)

Novartis Pharmaceuticals22 participantsStarted Jun 2012

Sunto-gun, Shizuoka, Japan • Koto, Tokyo, Japan • Fukuoka, Japan

TERMINATEDPhase 3

Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

NCT02951156

Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by Phase 3), parallel-arm study of avelumab in combination with various agents for the treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL).

Diffuse Large B-Cell Lymphoma

Pfizer29 participantsStarted Dec 2016

Duarte, California, United States • Louisville, Kentucky, United States • Louisville, Kentucky, United States +26 more locations

A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors

Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)

Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Related Searches

Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies

Use of a Patient Preferences Shared Decision-Making Encounter Tool in Clinical Practice for Patients With DLBCL and FL

Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma

Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL

tTF-NGR Phase I Study

The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma

Intra-Osseous Co-Transplant of UCB and hMSC

Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome

Interdisciplinary Case-Control Study of Non-Hodgkin's Lymphoma

Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas

A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL

Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies

Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL

A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma

PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study

Biomarker Guided Treatment in DLBCL

Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies